1
|
dos Anjos LR, de Souza VMR, Machado YAA, Partite VM, Aufy M, Dias Lopes G, Studenik C, Alves CR, Lubec G, Gonzalez ERP, Rodrigues KADF. Evidence of Guanidines Potential against Leishmania (Viannia) braziliensis: Exploring In Vitro Effectiveness, Toxicities and of Innate Immunity Response Effects. Biomolecules 2023; 14:26. [PMID: 38254626 PMCID: PMC10813298 DOI: 10.3390/biom14010026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Revised: 12/21/2023] [Accepted: 12/22/2023] [Indexed: 01/24/2024] Open
Abstract
Leishmaniasis is a complex group of infectious and parasitic diseases that afflict many thousands of individuals across five continents. Leishmaniasis treatment remains a challenge because it relies on drugsknown for their high toxicity and limited efficacy, making itimperative to identify new molecules that offer greater effectiveness and safety. This study sought to explore the impact of seven synthetic guanidine derivatives (LQOF-G1, LQOF-G2, LQOF-G6, LQOF-G7, LQOF-G32, LQOF-G35 and LQOF-G36) onthe parasite Leishmania (Viannia) braziliensis and in vitro macrophage infection by this parasite, as well as cytotoxic approaches in vitro models of mammalian host cells and tissues. The synthesized compounds showed purity ≥ 99.65% and effectively inhibited parasite growth. LQOF-G1 proved the most potent, yielding the best half-maximal inhibitory concentration (IC50) values against promastigotes (4.62 μmol/L), axenic amastigotes (4.27 μmol/L), and intracellular amastigotes (3.65 μmol/L). Notably, the antileishmanial activity of LQOF-G1, LQOF-G2, and LQOF-G6 was related to immunomodulatory effects, evidenced by alterations in TNF-α, IL-12, IL-10, nitric oxide (NO), and reactive oxygen species (ROS) levels in the supernatant of culture macrophages infected with L. (V.) braziliensis and coincubated with these compounds. LQOF-G2 and LQOF-G36 compounds exhibited vasodilator and spasmolytic effects at higher concentrations (≥100 μmol/L). Generally, LQOF-G1, LQOF-G2, and LQOF-G32 compounds were found to be nontoxic to assessed organs and cells. No toxic effects were observed in human cell lines, such as HEK-293, CaCo-2 and A549, at concentrations ≥ 500 μmol/L. Collectively, data have shown unequivocal evidence of the effectiveness of these compounds against L. (V.) braziliensis parasite, one of the causative agents of Tegumentary Leishmaniasis and Mucocutaneous Leishmaniasis in America.
Collapse
Affiliation(s)
- Luana Ribeiro dos Anjos
- Fine Organic Chemistry Lab, School of Sciences and Technology, São Paulo State University (UNESP), Presidente Prudente 19060-080, Brazil; (L.R.d.A.); (V.M.P.)
| | - Vanessa Maria Rodrigues de Souza
- Infectious Disease Laboratory—LADIC, Federal University of Parnaíba Delta—UFDPar, Campus Ministro Reis Velloso, São Benedito, Parnaíba 64202-020, Brazil; (V.M.R.d.S.); (Y.A.A.M.)
| | - Yasmim Alves Aires Machado
- Infectious Disease Laboratory—LADIC, Federal University of Parnaíba Delta—UFDPar, Campus Ministro Reis Velloso, São Benedito, Parnaíba 64202-020, Brazil; (V.M.R.d.S.); (Y.A.A.M.)
| | - Vitor Moreira Partite
- Fine Organic Chemistry Lab, School of Sciences and Technology, São Paulo State University (UNESP), Presidente Prudente 19060-080, Brazil; (L.R.d.A.); (V.M.P.)
| | - Mohammed Aufy
- Department of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna, Josef Holaubek Platz 2, UZAII (2D 259), 1090 Vienna, Austria; (M.A.); (C.S.)
| | - Geovane Dias Lopes
- Laboratório de Biologia Molecular e Doenças Endêmicas, Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, 4365, Manguinhos, Rio de Janeiro 21040-900, Brazil; (G.D.L.); (C.R.A.)
| | - Christian Studenik
- Department of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna, Josef Holaubek Platz 2, UZAII (2D 259), 1090 Vienna, Austria; (M.A.); (C.S.)
| | - Carlos Roberto Alves
- Laboratório de Biologia Molecular e Doenças Endêmicas, Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, 4365, Manguinhos, Rio de Janeiro 21040-900, Brazil; (G.D.L.); (C.R.A.)
| | - Gert Lubec
- Department of Neuroproteomics, Paracelsus Medical University, 5020 Salzburg, Austria;
| | - Eduardo Rene Perez Gonzalez
- Fine Organic Chemistry Lab, School of Sciences and Technology, São Paulo State University (UNESP), Presidente Prudente 19060-080, Brazil; (L.R.d.A.); (V.M.P.)
| | - Klinger Antonio da Franca Rodrigues
- Infectious Disease Laboratory—LADIC, Federal University of Parnaíba Delta—UFDPar, Campus Ministro Reis Velloso, São Benedito, Parnaíba 64202-020, Brazil; (V.M.R.d.S.); (Y.A.A.M.)
| |
Collapse
|